What question did this study set out to answer?

Compare the antihypertensive efficacy and safety of once-daily captopril 50 mg, hydrochlorothiazide 25 mg, and their fixed-dose combination against placebo in mild to moderate hypertension.

February 1, 1987British Journal of Clinical PharmacologyOpen Access

Comparative study of once‐daily administration of captopril 50 mg, hydrochlorothiazide 25 mg and their combination in mild to moderate hypertension.

View Full Paper

Ask AI

Bookmark

Why the study?

Does once-daily captopril, hydrochlorothiazide, or their combination reduce blood pressure in patients with mild to moderate hypertension compared to placebo?

Population

211 patients with mild or moderate hypertension, mean age 53.5 +/- 9.5 years (range 24-70)

Comparison

Captopril 50 mg, hydrochlorothiazide 25 mg, or… vs Placebo

Design

RCT, randomised, double-blind

Follow-up

8 weeks

Authors

JKJ G KayanakisUniversity of Vienna LBL BaulacUniversity of Vienna

Discussion

Member takes

Implication

Supports fixed-dose captopril-HCTZ preference in mild-moderate hypertension; confirms additive efficacy of ACEI-diuretic combination in RCT.

Key Points

Compare the antihypertensive efficacy and safety of once-daily captopril 50 mg, hydrochlorothiazide 25 mg, and their fixed-dose combination against placebo in mild to moderate hypertension.
Randomized, double-blind, placebo-controlled trial evaluating 211 patients (mean age 53.5 ± 9.5 years) with mild to moderate hypertension.
Assigned participants to once-daily captopril 50 mg, hydrochlorothiazide 25 mg, fixed-combination captopril 50 mg/hydrochlorothiazide 25 mg, or placebo for 8 weeks following a placebo run-in.
Evaluated blood pressure, heart rate, body weight, routine biochemistry, and adverse events 20–24 hours post-dose at baseline, 4, 6, and 8 weeks.
Mean percentage reductions in blood pressure from baseline reached high statistical significance at 8 weeks in both the captopril 50 mg and fixed-combination groups.
Fixed-combination captopril 50 mg/hydrochlorothiazide 25 mg achieved greater antihypertensive efficacy compared to placebo or either monotherapy alone.
Adverse event incidence remained low across all four treatment arms with no statistically significant differences, and zero participants withdrew due to side effects.

Structured PICO

Does once-daily captopril, hydrochlorothiazide, or their combination reduce blood pressure in patients with mild to moderate hypertension compared to placebo?

Population

211 patients with mild or moderate hypertension, mean age 53.5 +/- 9.5 years (range 24-70)

Intervention

Captopril 50 mg, hydrochlorothiazide 25 mg, or the fixed combination of captopril 50 mg and hydrochlorothiazide 25 mg once daily

Comparator

Placebo

Outcome

Blood pressure change from baseline at 8 weekssurrogate

The fixed combination of captopril 50 mg and hydrochlorothiazide 25 mg once daily provides superior blood pressure reduction compared to either monotherapy or placebo in mild to moderate hypertension, without increasing side effects.

Cite This Study

Kayanakis et al. (1987) studied this question.

synapsesocial.com/papers/6a71b68ef44fa9f079df7130 https://doi.org/10.1111/j.1365-2125.1987.tb03127.x

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Implication

Supports fixed-dose captopril-HCTZ preference in mild-moderate hypertension; confirms additive efficacy of ACEI-diuretic combination in RCT.

Comparative study of once‐daily administration of captopril 50 mg, hydrochlorothiazide 25 mg and their combination in mild to moderate hypertension.

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Comparative study of once‐daily administration of captopril 50 mg, hydrochlorothiazide 25 mg and their combination in mild to moderate hypertension.

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider